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ABSTRACT
Gastrointestinal symptoms occur frequently
among people with diabetes mellitus and are
associated with considerable morbidity.
Enteropathy, or large bowel dysfunction,
includes constipation, diarrhea and fecal
incontinence, and is particularly disturbing for
many patients. The pathogenesis of diabetic
enteropathy is complex, primarily related to
gastrointestinal autonomic dysfunction and
etiologically associated with chronic
hyperglycemia and diabetes duration. Since
there are many other non-iatrogenic and
iatrogenic causes of the cardinal symptoms of
large bowel dysfunction, patients suspected of
having diabetic enteropathy require detailed
evaluation. The management of patients with
diabetic enteropathy is challenging, and often
requires a multidisciplinary approach focusing
on a combination of symptom mitigation and
glycemic control.
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enteropathy; Management
INTRODUCTION
The gastrointestinal (GI) complications of
diabetes have become increasingly prevalent as
the rate of diabetes has increased [1]. The GI
tract manifestations of diabetes include
gastroparesis and enteropathy, and their
symptoms are classically caused by abnormal
GI motility, which is a consequence of diabetic
autonomic neuropathy involving the GI tract
[2]. Up to 75% of people with diabetes may
experience GI symptoms, leading to both a
significant decrement in patient quality of life
and an increase in health care costs. The classic
GI symptoms of diabetes include post-prandial
fullness with nausea, bloating, abdominal pain,
diarrhea, and/or constipation [1].
Gastroparesis is a well-recognized GI
manifestation of diabetes and is more
common in women. Delayed gastric emptying
has been demonstrated in between 27% and
65% of patients with type 1 diabetes mellitus
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(T1DM) and in up to 30% of patients with type
2 diabetes mellitus (T2DM) [3, 4]. Of note,
obesity appears to independently predict
symptoms of gastroparesis patients with T2DM
with comorbid sensory motor neuropathy [5].
There are multiple clinical features which
may be attributable to gastroparesis, includeing
nausea and vomiting as well as early satiety,
often combined with bloating and upper
abdominal pain. Deteriorating glycemic
control coupled with increased glucose
variability consequent upon mismatched
insulin action and nutrient absorption may
also suggest underlying gastroparesis. Up to
53% of patients may experience weight loss,
while as many as 24% of patients may actually
gain weight [4]. Symptom presentation can be
either acute or insidious, with a third of cases
having chronic symptoms with periodic
exacerbations, while a further third will
experience chronic progressive symptoms [4].
The diagnosis of gastroparesis is typically one
of exclusion, when other potential causes of
presenting symptoms have been evaluated and
postprandial gastric stasis is confirmed [6].
Whenever possible, patients should
discontinue medications that exacerbate
gastric dysmotility, in particular glucagon-like
peptide-1 (GLP-1)-receptor agonists, dipeptidyl
peptidase-4 (DPP-4) inhibitors, and metformin.
Other simple therapeutic approaches include
improving blood glucose control, increasing
dietary liquid content, consuming smaller
meals, and discontinuing the use of tobacco
and alcohol. Qualitative dietary changes should
also be made, namely, reducing the intake of
insoluble dietary fiber, foods high in fat, and
alcohol. Prokinetic agents (e.g.,
metoclopramide, erythromycin) may also be
helpful in managing the symptoms of
gastroparesis [6].
Enteropathy is a less well-recognized GI
manifestation of diabetes and can be
considered to be symptoms that affect the
large bowel. Clinical presentation includes
diarrhea, constipation, and fecal incontinence,
which can often be nocturnal [1], while overt
steatorrhea has been reported in a minority of
patients [7]. The nature of the symptoms
associated with diabetic enteropathy can by
definition be both distressing and often
multifaceted. Furthermore, many commonly
used drugs in diabetes, such as metformin,
statins, and the incretin-based therapies [7–9],
are associated with intestinal side effects, which
may confuse the issue with respect to
identifying and managing diabetic enteropathy.
Based on such considerations, this article
focuses on the pathophysiology, clinical
presentation, epidemiology, and management
of diabetic enteropathy, aiming to provide a




GI autonomic nerve dysfunction is the key
pathological factor with respect to enteropathy
in people with diabetes, including
abnormalities of motor function and visceral
hypersensitivity [10]. Additional factors
thought to play a role in the pathogenesis of
diabetic enteropathy include altered GI
hormone secretion and a proinflammatory
diathesis combined with a genetic
predisposition [10]. All these are enhanced in
the presence of acute or chronic hyperglycemia,
the latter exerting a particularly noxious effect
on the interstitial Cajal cells, ultimately leading
to impaired intestinal motility.
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While enteropathy can affect people with
T1DM and T2DM, it occurs more commonly in
people with T1DM [11]. There does not,
however, appear to be any differential
mechanism, with the relatively higher risk in
T1DM being potentially attributable to the
longer duration of hyperglycemia, which, in
turn, aggravates intestinal motility.
In both T1DM and T2DM, insulin-growth
factor I (IGF-I) are reduced, which may result in
smooth muscle atrophy, contributing to
impaired GI function [10]. Diabetes duration
and the level of glucose control are both factors
that are related to reduced IGF-1 expression in
diabetes, and this process may partly explain
the epidemiological associations between
diabetes duration and glycemic control with
diabetic enteropathy.
Other candidate mechanisms involved in the
pathogenesis of enteropathy in diabetes include
an impaired synthesis of neuronal nitric oxide,
which is an important neurotransmitter within
the bowel. Enhanced oxidative stress, an
autoimmune diathesis, and imbalance between
inhibitory and excitatory enteric neuropeptide
ratios have also been implicated as potential
contributory factors [10].
The diarrhea of diabetic enteropathy reflects
perturbations in small bowel motility and is
often associated with bacterial overgrowth [10].
Hyperglycemia and in particular glucose
variability may influence sphincter function.
Indeed, acute hyperglycemia inhibits external
anal sphincter function and decreases rectal
compliance, potentially leading to fecal
incontinence [12]. Furthermore, depression
rather than glycemic control may also be
linked with the development of GI symptoms
in diabetes, suggesting that emotional status
may be a factor, which many clinicians may




Epidemiology and Clinical Presentation
Constipation is a common presentation of
diabetic enteropathy, affecting up to 60% of
people with long-standing diabetes [13].
Complications arising from severe
constipation such as perforation and overflow
diarrhea are, however, relatively rare. Based on
studies with radio-opaque markers, there is
evidence for a generalized slowing in transit
constipation in the diabetic population [14].
However, there does not appear to be a
difference between subjects with and without
autonomic neuropathy [15].
Diarrhea is an important and often
debilitating feature of diabetic enteropathy
occurring in up to 20% of patients [16]. It may
happen at any time of the day, but it is typically
nocturnal. Characteristically, it is seen in
patients with poorly controlled diabetes with
co-existing peripheral and autonomic
neuropathy.
Fecal incontinence, particularly nocturnal,
related to internal and external sphincter
dysfunction is a particularly troublesome
symptom. Acute hyperglycemia and glucose
excursions have been shown to inhibit rectal
sphincter function, decreasing rectal
compliance and thus leading to fecal
incontinence [12, 17].
Enteropathic symptoms, in particular
diarrhea and constipation, occur with many
commonly used drugs in diabetes. Metformin is
the most commonly recognized drug in terms
of GI side effects, including abdominal
discomfort, bloating, nausea, anorexia,
diarrhea, and constipation. Up to 10% of
people receiving metformin have been
reported to experience one or more of these
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symptoms [7]; however, the incidence and
severity of such symptoms may be reduced by
slow dose titration, while dose reduction may
also be required in some individuals to mitigate
such symptoms and ensure therapy persistence.
Other blood-glucose-lowering therapies with
a mechanism of action involving the
modulation of intestinal physiology, such as
the incretin-based therapies and the
alpha-glucosidase inhibitors [17], are
associated with a variety of GI side effects,
with altered bowel function (either diarrhea or
constipation) occurring in up to 20% of people
receiving GLP-1 receptor agonist therapy and in
1–10% of people taking DPP-4 inhibitor therapy
[9].
GI side effects also occur in up to 5% of
people receiving statins, while fibrate therapy
may also be associated with GI adverse events,
including diarrhea and constipation in as many
as 10% of patients [18].
Due to the often debilitating nature of the
symptoms of diabetic enteropathy, patients can
often experience social isolation, relationship
difficulties, and employment and work
problems. Consequently, many patients—
particularly those with severe symptoms—may
become depressed and require psychological
support.
Investigation and Diagnosis
Given the high prevalence of enteropathic
symptoms, particularly in relation to many
drugs frequently prescribed for diabetes, prior
to embarking on any investigations [19] (see
Table 1) or making a presumptive diagnosis of
diabetic enteropathy, attention should be
focused on potential treatment changes. These
may include discontinuing, reducing the dose
of metformin, or switching to the modified
release preparation, which has been suggested
to induce fewer GI side effects [7]. The GLP-1
receptor agonists are commonly associated with
GI side effects, and switching between agents
within a class, reducing dose, or discontinuing
therapy are all potential considerations.
Furthermore, a trial in which any other
medications typically associated with GI
adverse effects are discontinued should also be
adopted. In addition, some diabetic foods may
exert a laxative effect, and as such should also
be discontinued in the setting of persistent
diarrhea.
In the presence of persisting symptoms,
despite appropriate therapeutic modifications
as outlined above, investigations such as
endoscopy, stool culture, and computed
tomography should be initiated to exclude
other causes (see Table 1).
Pancreatic exocrine insufficiency also needs
to be excluded as a potential cause of
enteropathy in diabetes. This is particularly
pertinent since pancreatitis occurs 2–4 times
more commonly in people with diabetes than
in the nondiabetic population [20]. Risk factors
for pancreatitis tend to cluster in diabetes,
including an increase in gall stone disease
consequent upon gall bladder dysmotility [21],
obesity, and the use of many medications such
as angiotensin-converting enzyme inhibitors
and diuretics that are associated with an
increase in the risk of pancreatitis [22]. Based
on such considerations, measurement of fecal
elastase should be one of the initial
investigations conducted when evaluating a
patient with potential diabetic enteropathy
(see Table 1).
Other causes of diarrhea also need to be
excluded, e.g., infectious diarrhea, celiac
disease, bile salt diarrhea, and the
concomitant use of drugs that may cause
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diarrhea such as metformin, GLP-1 receptor
agonists, DPP-4 inhibitors, proton pump
inhibitors, and statins (see Table 2).
Investigating colonic transit time may be
useful in terms of confirming a diagnosis of
enteropathy, using noninvasive radio-opaque
marker methods. The demonstration of reduced
anal sphincter tone, by barostat or manometry,
may also be useful with respect to confirming a
diagnosis of enteropathy [12, 13].
Patient questionnaires, such as the Diabetes
Bowel Symptom Questionnaire (DBSQ), provide
a specific measure of GI symptoms and glycemic
control in patients with diabetes [23] and as
such may be useful in quantifying the impact
on quality of life or the enteropathic symptoms
in people with diabetes.
Management of Diabetic Enteropathy
The management of enteropathy in diabetes
represents a considerable challenge and is
generally suboptimal, thus undoubtedly
prevention is better than cure. The
fundamental objectives of managing diabetic
enteropathy revolve around symptom relief and
glycemic control.
It is important to assess patients’ nutritional
status, especially in cases of combined
gastroparesis and diarrhea. The recognition of
dehydration, weight loss, and electrolyte
imbalance is particularly important and may
necessitate acute hospitalization and enteral
feeding, particularly in patients with [5%
weight loss in 3 months.
Table 1 Diagnostic approach to diabetic enteropathy
Differential diagnosis Features and diagnostic approach
Bacterial overgrowth in the small bowel Response to antibiotics
Celiac sprue Flat biopsy of the small bowel
Improved biopsy ﬁndings after GFD
Clinical response to GFD
Bile acid catharsis Increase in stool bile acids
Response to cholestyramine
Anorectal dysfunction Resting pressure or abnormal rectal sensation on anorectal manometrya
Fecal incontinence
Intestinal motility or secretory disorder Abnormal results on GI manometry or transit study
Response to opioids or clonidine
Lactose intolerance Abnormal results of lactose-hydrogen breath test
Response to lactose-free diet
Iatrogenic Intake of medication known to cause diarrhea
Response to withdrawal
GFD gluten-free diet, GI gastrointestinal
a Anorectal manometry is a test performed to evaluate patients with constipation or fecal incontinence. This test measures
anal sphincter muscle pressure, the sensation in the rectum, and the neural reﬂexes that are needed for normal bowel
movements
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Nutritional counseling with specialist
dietetic input is an important component of
the management of diabetic enteropathy, with
dietary manipulation (low fat/fiber,
small-portion meals) often providing
symptomatic benefit [10].
Bacterial overgrowth is found in up to 40%
of diabetic patients with diarrhea [11].
Consequently, the treatment of enteropathic
symptoms should include intermittent and
even potentially long-term administration of
selective antibiotics. Rifaximin is the most
extensively studied agent in this context,
improving symptoms in between 33% and
92% of patients while eradicating bacterial
overgrowth in up to 80% of patients [11].
Symptomatic benefit may also be achieved
with the use of opioid-based agents and, in the
event of severe refractory diarrhea, somatostatin
analogues may be useful [24], while loperamide
may provide benefit in the management of fecal
incontinence. In terms of somatostatin
analogue therapy, octreotide and lanreotide
are useful in a variety of diarrhea states, while
there is a suggestion that the longer half-life of
lanreotide may result in greater symptomatic
benefit [25].
Management of constipation revolves
around the use of traditional laxatives, and is
still primarily aimed at symptom relief. In
patients where abdominal pain is the main
symptomatic manifestation of enteropathy,
medications such as tricyclic and tetracyclic
antidepressants, gabapentin, and pregabalin
can be used with varying degrees of benefit [26].
Improving overall glucose control and, in
particular, limiting glucose variability are
important considerations in the management
of patients exhibiting diabetic enteropathy,
particularly in those in whom diarrhea is the
main symptomatic manifestation. The use of
multiple daily dosing insulin regimens, insulin
pump therapy, and continuous glucose
monitoring may be considered as therapeutic
options in such cases.
SUMMARY
Enteropathy or large bowel dysfunction
represents a major morbidity for many people
Table 2 Potential management algorithm for patients presenting with suspected enteropathy
1. Patient presenting with suspected enteropathy
2. Clinical evaluation (e.g., type and nature of symptoms, acute/chronic/duration, presence of other GI symptoms,
presence of other neuropathic symptoms/signs)
3. Investigate to exclude alternative causes (e.g., other bowel pathology, pancreatic insufﬁciency, functional infection)
4. Diagnosis of diabetic enteropathy conﬁrmed
5. Initiate stepwise therapeutic strategy:
Step 1: Ensure adequate hydration and commence antidiarrheal agents (e.g., loperamide, codeine)
Step 2: Improve metabolic control.
Step 3: If symptoms persist despite implementing steps 1 and 2, therapeutic trial of antibiotic therapy (e.g., rifaximin)
Step 4: If symptoms persist despite implementing steps 1, 2, and 3, add somatostatin analogue (e.g., octreotide/
lanreotide). Be aware these agents may inﬂuence blood glucose levels
Step 5: If pain is a major feature, then amitriptyline or pregabalin may provide beneﬁt
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with diabetes and can go unrecognized for a
long time. Thus, a high index of suspicion is
required in the case of persistent GI symptoms,
especially in patients with long-standing
diabetes and other chronic microvascular
complications, particularly neuropathy.
Diagnosis requires careful clinical evaluation
and exclusion of other potential causes, both
iatrogenic and non-iatrogenic. The
management of enteropathy remains
challenging, revolving around symptom
mitigation and optimization of glucose control.
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